Study of Patient Experiences in IDH-mutant Grade 2 Glioma Treatment Comparing Vorasidenib Drug Therapy, Radiotherapy, and Active Surveillance

What this Trial Is About

Researchers are evaluating the experiences of people diagnosed with IDH-mutant, grade 2 gliomas, a type of low-grade brain tumor. The study compares patient-reported quality of life, treatment-related symptoms, and anxiety levels among those receiving radiotherapy, those treated with the drug vorasidenib, and those under active surveillance. The study also aims to see how practical it is to use patient-reported outcome measures PROMs in routine care to help improve treatment pathways. Participants are divided into three groups based on their treatment plan one group receives vorasidenib, an IDH inhibitor drug another undergoes radiotherapy for remaining or recurring tumor and the third group is monitored through active surveillance with regular MRI scans and clinical evaluations. Regardless of treatment, all participants complete questionnaires every six months for two years to provide their perspectives. Throughout the study, participants provide information via questionnaires about their symptoms and quality of life. These patient-reported outcomes help researchers understand the impact of each treatment approach. The main outcome measured is the characterization and comparison of patients experiences over three years. This includes monitoring their wellbeing and any critical issues to support better care. The total participation time is at least two years with ongoing follow-up assessments.

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared